BioMed X, an independent research institute based in Germany, has partnered with pharmaceutical giant Sanofi to begin their first research project. This collaborative effort aims to develop an innovative computational platform called the “Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates” (VPE). The ultimate goal is to enhance the prediction accuracy of drug candidate efficacy, specifically for first- or best-in-class drugs, in virtual patient populations. This pioneering platform will address a pressing issue in the pharmaceutical industry – the staggering 90% failure rate that new drug candidates encounter during clinical development.
Leading this groundbreaking research team is Dr. Douglas McCloskey, a distinguished scientist selected jointly by Sanofi and the management of the BioMed X Institute. Dr. McCloskey expressed his motive, stating, “Most drug candidates fail in clinical development due to a lack of effectiveness compared to existing treatment standards. Our objective is to create a platform that can thoroughly evaluate drug development candidates using virtual patients, selecting the most promising ones to advance to clinical trials.” Dr. McCloskey further emphasized the significance of this endeavor, stating, “To take on this challenge, our team at BioMed X will push the boundaries of in silico [aka computational medicine] drug discovery and development, capitalizing on our AI expertise and leveraging guidance from industry partners.”
Christian Tidona, Founder and Managing Director of the BioMed X Institute, shared his excitement about this collaboration, adding, “After two years of successful collaboration on AI-driven drug discovery and development initiatives with our strategic partner, AION Labs in Israel, we are thrilled to embark on our first AI-based research team in Heidelberg, Germany, alongside our new pharma partner, Sanofi.” The VPE team, centered around the “Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates,” will be joining eight existing research teams at the BioMed X Institute in Germany. This initiative is one of four new projects initiated by BioMed X in 2023.
The strategic collaboration between BioMed X and Sanofi holds considerable promise for revolutionizing and streamlining the future of drug development, ultimately benefiting patients worldwide.
The whytry.ai article you just read is a brief synopsis; the original article can be found here: Read the Full Article…
